Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics

Apellis Pharmaceuticals, Inc. (APLS): $45.43

0.21 (+0.46%)

POWR Rating

Component Grades














  • APLS scores best on the Growth dimension, with a Growth rank ahead of 60.26% of US stocks.
  • APLS's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • APLS's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

APLS Stock Summary

  • With a price/sales ratio of 71.52, Apellis Pharmaceuticals Inc has a higher such ratio than 96.97% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 56.65 for Apellis Pharmaceuticals Inc; that's greater than it is for 99.48% of US stocks.
  • Revenue growth over the past 12 months for Apellis Pharmaceuticals Inc comes in at -73.44%, a number that bests only 1.7% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Apellis Pharmaceuticals Inc, a group of peers worth examining would be FOLD, MNOV, PXLW, CRDF, and EYEN.
  • APLS's SEC filings can be seen here. And to visit Apellis Pharmaceuticals Inc's official web site, go to www.apellis.com.

APLS Valuation Summary

  • APLS's price/earnings ratio is -12.4; this is 133.97% lower than that of the median Healthcare stock.
  • APLS's price/earnings ratio has moved up 13.1 over the prior 46 months.
  • APLS's EV/EBIT ratio has moved up 11 over the prior 46 months.

Below are key valuation metrics over time for APLS.

Stock Date P/S P/B P/E EV/EBIT
APLS 2021-08-31 22.8 -40.5 -12.4 -13.6
APLS 2021-08-30 22.6 -40.2 -12.4 -13.5
APLS 2021-08-27 23.0 -40.8 -12.5 -13.7
APLS 2021-08-26 22.2 -39.5 -12.1 -13.3
APLS 2021-08-25 21.3 -37.9 -11.6 -12.7
APLS 2021-08-24 21.2 -37.7 -11.6 -12.7

APLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • APLS has a Quality Grade of C, ranking ahead of 54.9% of graded US stocks.
  • APLS's asset turnover comes in at 0.31 -- ranking 148th of 682 Pharmaceutical Products stocks.
  • FENC, ACST, and CARA are the stocks whose asset turnover ratios are most correlated with APLS.

The table below shows APLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.310 1 -0.607
2021-03-31 0.294 1 -0.434
2020-12-31 0.305 1 -0.496
2020-09-30 0.001 1 -1.018
2020-06-30 0.000 NA -1.210
2020-03-31 0.000 NA -2.534

APLS Price Target

For more insight on analysts targets of APLS, see our APLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $67.81 Average Broker Recommendation 1.38 (Strong Buy)

APLS Stock Price Chart Interactive Chart >

Price chart for APLS

APLS Price/Volume Stats

Current price $45.43 52-week high $73.00
Prev. close $45.22 52-week low $27.50
Day low $44.44 Volume 843,600
Day high $46.26 Avg. volume 1,059,366
50-day MA $43.25 Dividend yield N/A
200-day MA $42.48 Market Cap 4.84B

Apellis Pharmaceuticals, Inc. (APLS) Company Bio

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.

APLS Latest News Stream

Event/Time News Detail
Loading, please wait...

APLS Latest Social Stream

Loading social stream, please wait...

View Full APLS Social Stream

Latest APLS News From Around the Web

Below are the latest news stories about Apellis Pharmaceuticals Inc that investors may wish to consider to help them evaluate APLS as an investment opportunity.

Apellis Pharmaceuticals Q4 2021 Earnings Preview

Apellis Pharmaceuticals (NASDAQ:APLS) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is -$1.60 (-272.0% Y/Y) and the consensus Revenue Estimate is $8.78M (-96.5% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue...

Seeking Alpha | February 25, 2022

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.

Yahoo | February 23, 2022

Why Apellis (APLS) Might Surprise This Earnings Season

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 23, 2022

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 4:30 p.m. ET. To access the live call by phone, please pre-register for the call here. The conference ID is 8184953. A live audio webcast of the event and accompanying sli

Yahoo | February 22, 2022

Read More 'APLS' Stories Here

APLS Price Returns

1-mo 6.77%
3-mo -17.37%
6-mo -6.85%
1-year -34.95%
3-year 72.67%
5-year N/A
YTD -3.91%
2021 -17.34%
2020 86.81%
2019 132.15%
2018 -39.22%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6687 seconds.